Low-dose rivaroxaban failed to improve outcomes in patients with worsening heart failure, reduced ejection fraction, and underlying coronary disease without atrial fibrillation in the COMMANDER HF trial. The trial involved over 5,000 patients from 628 sites across 28 countries who were randomly assigned to rivaroxaban 2.5 mg, taken orally twice daily, or matching placebo in ...
Thrombin inhibition no help in worsening heart failure: COMMANDER HF
By Nicola Garrett
30 Aug 2018